Microbiotherapy in Characterized Depressive Disorder (PROMOOD)

A Phase II, Prospective, Multicenter Study Assessing the Contribution and Tolerance of a Multi-targeted Microbiotherapy in Addition to Venlafaxine, After Failure of a First-line Antidepressant Treatment in Depressed Patients

The study aims to evaluate the contribution of a multi-targeted microbiotherapy at 12 weeks in depressed-patients in a situation of failure of a 1st line of antidepressant treatment and treated in add-on with a 2nd antidepressant, venlafaxine.

Study Overview

• Status: Recruiting
• Conditions: Depressive Disorder; Depression; Depressive Disorder, Major
• Intervention / Treatment: Dietary supplement: microbiotherapy (GynMDD); Other: placebo

Detailed Description

Depression is the most common psychiatric illness and has major personal, societal and economic consequences.

Increase in the disease prevalence is significantly associated with certain somatic pathologies, including metabolic diseases and functional intestinal disorders. From a therapeutic point of view, approximately 2/3 patients are not in remission after first-line antidepressant treatment. Moreover, 20 to 30% patients resist at all the therapeutic strategies classically proposed in this indication.

The identification of new therapeutic strategies is therefore a major challenge, especially for patients with chronic depression resistant to standard treatments.

Various research studies have shown the involvement of inflammatory mechanisms in depression. Thus, the increase in the disease prevalence is significantly associated with certain somatic pathologies, in particular metabolic diseases, a certain number of which are linked to abnormalities of the intestinal microbiota. In this context, the use of probiotics is interesting because some have antidepressant effects, anti-inflammatory and metabolic properties. However, even if a few studies have shown an antidepressant effect of probiotics with improvement of biological markers of inflammation, it seems that the use of probiotics alone is not sufficient for lasting results on depressive symptoms.

The PROMOOD clinical research project fits into this context. We propose to carry out a multicenter clinical study with the product developed by GYNOV (GynMDD® multitarget compound with 3 active ingredients: an amino acid (L-glutamine), an ingredient purified from a plant extract (Cavacurmine) and a probiotic (Lactobacillus rhamnosus GG). In a preclinical study carried out at the CNRS on 144 mice, a synergy of action between these 3 ingredients was demonstrated on the anxio-depressive systems, resulting in an improvement far greater than the expected effect of composition and comparable to a reference injectable antidepressant (clomipramine).

In theses context, the microbiotherapy proposed in this project is very original because:

• a multi-target approach targeting several mechanisms of action: intestinal permeability, glutamine/glutamate/GABA cycle, insulin resistance, immunomodulation, oxidative stress;
• prospect of an optimization/simplification of care;
• It is very acceptable for patients both from the point of view of tolerance and from the economic point of view.

With a phase II, prospective, multicenter design, this study aims to evaluate the contribution and the tolerance of a multi-targeted microbiotherapy in addition to venlafaxine, in a second-line antidepressant treatment. The treatment will be delivered during 12 weeks.

Baseline measures will be compared to those obtained during the treatement administration (every week) and after the treatment administration (every week for the next 12 weeks).

• Study Type: Interventional
• Enrollment (Anticipated): 92
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Emmanuel HAFFEN, PhD; Phone Number: 0033 3 81 21 90 07; Email: emmanuel.haffen@univ-fcomte.fr
• Study Contact Backup: Name: Magali NICOLIER, PhD; Phone Number: 0033 3 81 21 90 07; Email: mnicolier@chu-besancon.fr

Study Locations

• France
  • Besançon, France, 25030
    • Recruiting
    • Emmanuel HAFFEN
    • Contact: Emmanuel HAFFEN, Prof.; Phone Number: +33381219007; Email: emmanuel.haffen@univ-fcomte.fr
    • Contact: Magali NICOLIER, PhD; Phone Number: +33 3 81 21 90 07; Email: mnicolier@chu-besancon.fr
  • Bordeaux, France, 33000
    • Not yet recruiting
    • Centre Hospitalier Spécialisé Charles Perrens
    • Contact: Bruno AOUIZERATE, MD PhD; Email: bruno.aouizerate@u-bordeaux.fr
    • Principal Investigator: Bruno AOUIZERATE, MD PhD
  • Clermont-Ferrand, France, 63000
    • Not yet recruiting
    • CHU de Clermont-Ferrand
    • Contact: Pierre-Michel LLORCA, MD PhD; Email: pmllorca@chu-clermontferrand.fr
    • Principal Investigator: Pierre-Michel LLORCA, MD PhD
  • Créteil, France, 94000
    • Recruiting
    • Hôpital Henri Mondor / APHP
    • Contact: Marion LEBOYER, MD PhD; Email: marion.leboyer@inserm.fr
    • Principal Investigator: Marion LEBOYER, MD PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 61 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of unipolar MDD (Diagnostic and Statistical Manual of Mental Disorders V [DSM-V], QIDS-C16≥15)
• No response at a first antidepressant
• under venlafaxine
• Signed informed consent form
• Subjects affiliated to or beneficiary from a French social security regime

Exclusion Criteria:

• Contraindications to probiotic administration
• Allergy to one of the compounds of the multi-target probiotic or the placebo
• consuming probiotic-based dietary supplements
• Patient with other psychiatric disorders, except social anxiety disorder, generalized anxiety disorder and nicotine use disorder
• Patient with a serious and/or progressive medical condition, including chronic inflammatory pathologies or autoimmune diseases requiring long-term anti-inflammatory treatment (including corticosteroid therapy) or immunosuppressant.
• Patient with a recent infectious episode likely to require antibiotic therapy.
• Patient presenting with a suicidal risk assessed by the suicide item of the QIDS-C16 scale (score item 12 of the QIDS-C16 >2)
• Other concomitant antidepressant and/or lithium and/or anti-inflammatory treatment for the duration of the study
• Subject under measure of protection or guardianship of justice
• Subject beneficiary from a legal protection regime
• Subject unlikely to cooperate or low cooperation stated by investigator
• Subject not covered by social security
• Pregnant woman
• Subject being in the exclusion period of another study or provided for by the "National Volunteer File

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Microbiotherapy in addition of venlafaxin; Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the microbiotherapy during 12 weeks. The microbiotherapy is GynMDD devlopped by Gynov and which is composed by a probiotic associated to polyphenol and an amino acid.	Dietary supplement: microbiotherapy (GynMDD); multi-target microbiotherapy add-on venlafaxine
Placebo Comparator: calibration arm; Subjects suffering of MDD and treated by venlafaxine in a second-line assigned to start the placebo therapy during 12 weeks.	Other: placebo; placebo add-on venlafaxine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline Quick Inventory of Depressive Symptomatology (QIDS-C16) at 12 weeks	The QIDS-C16 is a 16-item scale that is clinician-rated; it is designed to assess the severity of depressive symptoms. The QIDS-C16 total score ranges from 0-27. Scores ranging from 0 to 10 correspond with no to mild depression, while scores >/= 11 correspond to moderate to severe depression. A negative change indicates improvement in the subject's depression, and a positive change indicates a worsening of the subject's depression.	baseline (Day 0), Week 12 (W12) post-treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Severity of depressive symptoms evaluated by the clinician	The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.	baseline (Day 0), at the end of therapy (week 12 (W12)
Change from Severity of depressive symptoms evaluated by the patient	Score achieved on the validated self-reported (QIDS-SR16) evaluating the severity of depressive symptoms. QIDS-SR-16 is a standard questionnaire "The Quick Inventory of Depressive Symptomatology" (16-Item) (Self-Report). This covers questions on falling asleep, sleep during the night, waking up , sleeping too much, feeling sad ,appetite, weight, concentration , how they view themselves, thoughts of death and suicide, general interests, energy levels, feeling slowed down , feeling restless.	baseline (Day 0), at the end of therapy (week 12 (W12)
Evaluation of treatment observance	A treament observance book was complied by patient during the 12 weeks of therapy	baseline (Day 0), at the end of therapy (week 12 (W12)
Change from Health related Quality of Life (HrQoL)	HrQOL will be assessed using health status measures of the EuroQuality of Life Five Dimensions (EQ-5D-5L)	baseline (Day 0), at the end of therapy (week 12 (W12)
Change from anxiety	anxiety assessed using Brief Anxiety Scale of Tyrer (BAS)	baseline (Day 0), at the end ot therapy (week 12 (W12)
Change from digestive health	digestive evaluation assessed by digestive health scale, scale developped by gastroenterlogists (https://www.worldgastroenterology.org/search?cx=005474681532606414716%3AWMX-367025812&cof=FORID%3A9&ie=UTF-8&q=digestive+health+evaluation)	baseline (Day 0), at the end ot therapy (week 12 (W12)
Change from serum Inflammatory biological markers	inflammatory inflammatory levels (CRP, Il-1b, Il-6 and TNF-a) in blood samples	baseline (Day 0), at the end ot therapy (week 12 (W12)
Change from Biological markers of intestinal dysbiosis	zonulin and serobank levels in blood samples	baseline (Day 0), at the end ot therapy (week 12 (W12)
Change from Metagenomic shotgun sequencing of gut microbiota	preforming metagenomic shotgun sequencing of fecal DNA to determine the changes in the intestinal microbiota composition, diversity and functionality	baseline (Day 0), at the end ot therapy (week 12 (W12)

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Besancon
• Collaborators: Fondation FondaMental; GYNOV
• Investigators: Principal Investigator: Emmanuel HAFFEN, MD PhD, CHU de Besancon

Study record dates

Study Major Dates

• Study Start (Actual): June 8, 2022
• Primary Completion (Anticipated): July 1, 2024
• Study Completion (Anticipated): December 1, 2024

Study Registration Dates

• First Submitted: February 18, 2022
• First Submitted That Met QC Criteria: March 4, 2022
• First Posted (Actual): March 15, 2022

Study Record Updates

• Last Update Posted (Actual): September 9, 2022
• Last Update Submitted That Met QC Criteria: September 8, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: depression; microbiotherapy
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Pathologic Processes; Mood Disorders; Depression; Depressive Disorder; Disease; Depressive Disorder, Major
• Other Study ID Numbers: 2021/621

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No